Skip to main content

Table 2 Adjusted HbA1c reduction over 12 month period in patients switching from premix to glargine*

From: Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary care-based analysis

Variable Type 1 (n = 183) Type 2 (n = 345)
No. Δ HbA 1c (%) p-value No. Δ HbA 1c (%) p-value
Overall 183 -0.67 <0.001 345 -0.53 <0.001
By baseline HbA1c level
   ≥ 7% 151 -0.67 <0.001 306 -0.56 <0.001
   ≥ 8% 128 -0.80 <0.001 255 -0.68 <0.001
   ≥ 9% 86 -1.06 <0.001 169 -0.84 <0.001
   ≥ 10% 46 -1.74 <0.001 88 -1.20 <0.001
  1. OAD = oral antidiabetic drugs; HbA1c = glycated haemoglobin.
  2. *Adjusted for demographic and clinical covariates including age, weight, hypoglycaemia, concomitant use of OADs and baseline HbA1c (in the 3 months prior to insulin initiation).
  3. †p-values by the paired t-test for difference in mean HbA1c following switch from premix to glargine.